Introduction
============

Colorectal cancer (CRC) is the second and third most common cancer of women and men worldwide, respectively ([@ref-4]). The amount of deaths due to CRC ranked the second among all cancer types in 2018 ([@ref-4]). CRC is a heterogeneous disease with various genetic events ([@ref-14]; [@ref-24]). Target therapy such as anti-epidermal growth factor receptor (EGFR) therapy has been developed for metastatic CRC ([@ref-6]).

KRAS is an effector molecule that makes the signal transduction from ligand-bound EGFR to the nucleus ([@ref-20]). KRAS has intrinsic GTPase activity and it binds to GTP to active downstream pathway, such as RAS/RAF/MAPK and PI3K/AKT pathways, to promote cell proliferation. Normally, the GTPase activating proteins would enhance the GTPase activity of KRAS and transform the status of GTP-bound KRAS into a status of GDP-bound KRAS, terminating the downstream signaling. However, some types of KRAS mutation could impair the GAP binding to KRAS and lead to a continuous GTP-bound KRAS status to promote the proliferation related pathways and cancer development ([@ref-8]). The mutation of KRAS would also impair the efficacy of EGFR-targeted therapy ([@ref-20]). KRAS mutation is found in about 33--45% of CRC ([@ref-34]). Hence, the KRAS testing is recommended for CRC patients who would receive anti-EGFR therapy. The anti-EGFR therapy is limited to KRAS wild type (WT) CRC patients but not KRAS mutant (MT) patients ([@ref-21]).

Despite the KRAS mutation status as a biomarker for the anti-EGFR therapy of CRC patients, whether it is an independent prognostic factor in CRC was controversial. In metastatic CRC, there were studies showed that KRAS MT patients had worse progression-free survival (PFS) ([@ref-22]; [@ref-31]) or overall survival (OS) ([@ref-22]) than KRAS WT patients, while other study found there was no association between KRAS mutation status and PFS or OS of CRC patients ([@ref-17]). Among stage II and III CRC, there were studies found KRAS mutation would worsen the OS ([@ref-25]) or disease-free survival (DFS) ([@ref-10]; [@ref-19]) of patients while other study found KRAS mutation was not associated with the OS or recurrence-free survival (RFS) of CRC patients ([@ref-26]). In stage III colon cancer, a study found KRAS mutation status was not associated with the OS or RFS or DFS of patients ([@ref-23]), while more recently studies found the KRAS mutation would worsen the DFS ([@ref-32]) or survival after recurrence (SAR) ([@ref-33]) of patients. To be noted, most of these studies included with limited amount of CRC patients who had KRAS testing.

The Surveillance, Epidemiology, and End Results (SEER) database of the National Cancer Institute is a national collaboration program of United States, covering 34.6% of the national population. It collects the incidence, survival and treatment data of cancer patients. There was a SEER based study ([@ref-7]) on the association between KRAS mutation status and the OS of patients with left or right side CRC. However, despited that CRC is an aggressive disease, the median age at diagnosis for colon cancer patients is 68 years in men and 72 years in women, respectively; for rectal cancer patients it is 63 years in both men and women ([@ref-30]). In this case, competing risk events might be involved, as the elders might die from diseases other than CRC such as cardiovascular disease ([@ref-39]). Competing risk models such as the cumulative incidence function (CIF) model and Fine-Gray regression for proportional hazards modeling of the subdistribution hazard (SH) model ([@ref-1]) should be used for the prognostic analyses of population based studies of CRC.

A nomogram is a useful method to predict the probability of patients' clinical outcomes ([@ref-2]). It has compared favorably to traditional TNM staging systems in the prognostic prediction in a series of cancers ([@ref-3]; [@ref-12]). To our knowledge, there is currently no nomogram constructed for predicting the outcomes of CRC patients who had KRAS testing.

Here we performed a SEER based study to evaluate the association between KRAS mutation status and the cancer specific survival (CSS) of CRC patients by using competing risk analyses. We also drew an SH model based nomogram for the cancer specific death prediction of CRC patients who had KRAS testing.

Methods
=======

Cohort information
------------------

The SEER based cohort was selected using SEER\*Stat 8.3.5 software (SEER ID: daid). The access to Collaborative Stage Site-Specific Factor 9 (KRAS mutation status) was granted by the National Cancer Institute (NCI). We included patients who met the inclusion criteria as the follows: (1) it should be a CRC patient who had KRAS testing; (2) it should include sufficient clinicopathological information of the variables in current study ([Table 1](#table-1){ref-type="table"}). As the information of KRAS testing was collected since 2010, we only included patients who were diagnosed equal to or after 2010. Finally, as shown in [Fig. S1](#supp-1){ref-type="supplementary-material"}, to find an adequate follow-up time, the patients diagnosed between 2010 and 2012 were included. For tumor location, left side means the tumors in splenic flexure, descending colon, sigmoid and rectosigmoid junction, and right side means the tumors in cecum, ascending colon, hepatic flexure and transverse. We defined the median follow-up as the median observed survival time. The last follow-up time was December 31, 2015.
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###### The characteristic of each included variables in KRAS MT and KRAS WT patients.
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  Characteristics           KRAS MT   KRAS WT   *p* Value           
  ------------------------- --------- --------- ----------- ------- -------------
  Age                                                               **0.045**
  \<29                      38        1.05      70          1.30    
  30--39                    145       4.01      246         4.58    
  40--49                    503       13.91     738         13.75   
  50--59                    820       22.68     1,261       23.50   
  60--69                    992       27.43     1,435       26.74   
  70--79                    749       20.71     995         18.54   
  \>=80                     369       10.20     622         11.59   
  Sex                                                               **0.023**
  Female                    1,697     46.93     2,387       44.48   
  Male                      1,919     53.07     2,980       55.52   
  Race                                                              **\<0.001**
  White                     2,757     76.24     4,264       79.45   
  African Americans         518       14.33     598         11.14   
  Others                    328       9.07      490         9.13    
  Unknown                   13        0.36      15          0.28    
  Location                                                          **\<0.001**
  Left                      1,208     33.41     2,268       42.26   
  NOS                       97        2.68      160         2.98    
  Rectum                    665       18.39     992         18.48   
  right                     1,646     45.52     1,947       36.28   
  Tumor size                                                        0.086
  \<=2 cm                   399       11.03     647         12.06   
  \>6                       674       18.64     997         18.58   
  2--4                      855       23.64     1,363       25.40   
  4--6                      1,054     29.15     1,476       27.50   
  N                         634       17.53     884         16.47   
  Surgery                                                           **0.005**
  No                        816       22.57     1,079       20.10   
  Yes                       2,800     77.43     4,288       79.90   
  Stage                                                             **\<0.001**
  0/(Tis)                   13        0.36      12          0.22    
  I                         202       5.59      384         7.15    
  II                        461       12.75     817         15.22   
  III                       887       24.53     1,494       27.84   
  IV                        2,020     55.86     2,615       48.72   
  Unknown                   33        0.91      45          0.84    
  Grade                                                             **\<0.001**
  Low grade (I & II)        2,502     69.19     3,490       65.03   
  High grade (III & IV)     712       19.69     1,370       25.53   
  NOS                       402       11.12     507         9.45    
  Regional nodes positive                                           **0.025**
  \>=10                     1,196     33.08     1,726       32.16   
  0                         903       24.97     1,485       27.67   
  1--3                      880       24.34     1,212       22.58   
  4--9                      637       17.62     944         17.59   
  Radiotherapy                                                      0.383
  No                        3,058     84.57     4,576       85.26   
  Yes                       535       14.80     772         14.38   
  Unknown                   23        0.64      19          0.35    
  Chemotherapy                                                      **0.002**
  No                        924       25.55     1,534       28.58   
  Yes                       2,692     74.45     3,833       71.42   
  Marital status                                                    0.237
  Married                   1,988     54.98     2,958       55.11   
  Unmarried                 1,464     40.49     2,204       41.07   
  Unknown                   164       4.54      205         3.82    

**Note:**

KRAS MT, KRAS mutant; KRAS WT, KRAS wild type; the widowed or single (never married or having a domestic partner) or divorced or separated patients was defined as unmarried; Tis, Tumor in situ; *p* value referred to the difference between MT and WT KRAS patients; the significant *p* values were bolded.

Statistical analyses
--------------------

The chi-square test was applied for the comparisons of difference variables between KRAS WT and KRAS MT CRC patients. The cumulative incidences of death (CID) was estimated for cancer related deaths and non-cancer related deaths. Multivariate SH model, which involved all variables, was used to assess the CSS of CRC patients. SH model based nomogram was constructed to predict the 1-year, 2-year and 3-year CSS of CRC patients who had KRAS testing. To be noted, many prediction factors in one model might cause over-fitting. Hence, we used the variable selection to improve the interpretation and the accuracy of prediction of the competing nomogram ([@ref-11]). Penalized variable selection was performed by using methods of least absolute shrinkage and selection operator (LASSO), measure--correlate--predict (MCP) and smoothly clipped absolute deviation (SCAD) to select variables for SH model based nomogram. This nomogram was internally validated by discrimination and calibration with 1,000 times bootstraps ([@ref-2]). The calibration curves and the area under the curve of receiver operating characteristic curve (AUC) were used for discrimination and calibration, respectively.

The statistical analyses of current study were performed by a series of packages in R version 3.5.1. The detailed using of those packages could be found in our previous published study ([@ref-9]). We considered a *p*-value less than 0.05 as statistically significant.

Results
=======

Cohort information
------------------

As shown in [Table 1](#table-1){ref-type="table"}, there were totally 8,983 CRC patients (3,616 KRAS MT patients and 5,367 KRAS WT patients) included in current study. Significant differences were found between KRAS MT and KRAS WT patients among variables of age, race, location, surgery, tumor stage, grade, positive regional nodes amount, and chemotherapy experience (*p* \< 0.05). In detail, compared with KRAS WT patients, the KRAS MT patients had more African American race (14.33% vs. 11.14%), more occurrence in right side of the colon (45.52% vs. 36.28%), less surgery performance (77.43% vs. 79.90%), more metastatic site (55.86% vs. 48.72%), lower grade (grade III & IV: 19.69% vs. 25.53%), and more chemotherapy experience (74.45% vs. 71.42%). The median follow-time were 30 months and 36 months for KRAS MT and KRAS WT, respectively. In KRAS MT patients, the death rate caused by cancer and other reasons were 49.89% and 13.69%, respectively. In KRAS WT patients, the death rate caused by cancer and other reasons were 42.59% and 14.83%, respectively.

KRAS MT patients had worse outcomes than KRAS WT patients
---------------------------------------------------------

The CIF plots showed that the KRAS MT patients had a worse CSS than KRAS WT patients (*p* \< 0.001, [Fig. 1A](#fig-1){ref-type="fig"}). We further performed subgroup analysis of KRAS mutation status among different AJCC 7th stages and tumor locations. The CIF plots found that KRAS mutation had no association with the CSS of stage I (*p* = 0.347, [Fig. 1B](#fig-1){ref-type="fig"}) and stage II (*p* = 0.093, [Fig. 1C](#fig-1){ref-type="fig"}) CRC patients while it contributed to worse CSS in stage III (*p* = 0.009, [Fig. 1D](#fig-1){ref-type="fig"}) and stage IV (*p* = 0.0013, [Fig. 1E](#fig-1){ref-type="fig"}) CRC patients. In addition, the CIF plots showed that KRAS mutation was a hazard factor for the CSS of patients with cancers in the location of left colon, right colon and rectum (*p* \< 0.001, [Fig. 2](#fig-2){ref-type="fig"}).

![CSS of CRC patients with different stages according to KRAS status by CIF plot.\
CIF plots of KRAS status and the prognosis of CRC in overall population (A) and stage I--IV CRC patients (B--E).](peerj-08-9149-g001){#fig-1}

![CSS of CRC patients with differed location according to KRAS status by CIF plot.\
CIF plots of KRAS status and the prognosis of CRC in locations of unknown (A), left colon (B), right colon (C) and rectum (D) NOS, not otherwise specified.](peerj-08-9149-g002){#fig-2}

As shown in [Table 2](#table-2){ref-type="table"}, the multivariate SH model showed that KRAS MT patients had worse CSS (Hazard ratio (HR) = 1.10, 95% CI (95% confidence index) = 1.04--1.17, *p* \< 0.05) than KRAS WT patients. Further subgroup analysis found the KRAS mutation was an independent risk factor for the CSS of stage III (HR = 1.28 (95% CI \[1.09--1.49\]), *p* \< 0.05) and stage IV (HR = 1.14 (95% CI \[1.06--1.23\]), *p* \< 0.05) CRC patients. Moreover, we found KRAS shorten the CSS in patients with cancers occurred at left colon (HR = 1.28 (95% CI \[1.15--1.42\]), *p* \< 0.05) and rectum (HR = 1.23 (95% CI \[1.07--1.43\]), *p* \< 0.05) but not right colon (HR = 1.07 (95% CI \[0.97--1.19\]), *p* \> 0.05).
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###### Subgroup analysis of KRAS mutation status and the prognosis of CRC patients.

![](peerj-08-9149-g007)

  Group              Patients amount   KRAS MT vs. KRAS WT
  ------------------ ----------------- -------------------------
  All                8,983             **1.10 \[1.04--1.17\]**
  Stage I            586               1.30 \[0.62--2.70\]
  Stage II           1,278             1.27 \[0.95--1.69\]
  Stage III          2,381             **1.28 \[1.09--1.49\]**
  Stage IV           4,635             **1.14 \[1.06--1.23\]**
  Unknown location   257               1.01 \[0.69--1.49\]
  Left               3,476             **1.28 \[1.15--1.42\]**
  Right              3,593             1.07 \[0.97--1.19\]
  Rectum             1,657             **1.23 \[1.07--1.43\]**

**Note:**

KRAS MT, KRAS mutant; KRAS WT, KRAS wild type; HR, Hazard ratios; 95% CI, 95% confidence intervals; the significant results were bolded.

Multivariate SH analyses of each variable for the CSS of KRAS MT and KRAS WT CRC patients
-----------------------------------------------------------------------------------------

As shown in [Table 3](#table-3){ref-type="table"}, the multivariate SH model identified the absence of surgery, higher tumor stage and grade, and unmarried status as risk factors for both KRAS MT and KRAS WT CRC patients (HR \> 1, *p* \< 0.05). We observed there was no significant association between sex and the prognosis in neither KRAS MT nor KRAS WT CRC patients (*p* \> 0.05).
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###### Multivariate SH analyses of each variables in KRAS MT and WT patients.
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  Characteristics           SH model                     
  ------------------------- ---------------------------- ---------------------------
  Age                                                    
  \<29                      Reference                    Reference
  30--39                    0.58 \[0.36--0.94\]          1.19 \[0.85--1.66\]
  40--49                    0.71 \[0.46--1.11\]          1.05 \[0.77--1.44\]
  50--59                    0.72 \[0.46--1.13\]          1.11 \[0.82--1.51\]
  60--69                    **0.59 \[0.38--0.92\]**      1.03 \[0.76--1.40\]
  70--79                    **0.57 \[0.37--0.90\]**      0.99 \[0.72--1.36\]
  \>=80                     **0.58 \[0.36--0.94\]**      0.93 \[0.66--1.31\]
  Sex                                                    
  Female                    Reference                    Reference
  Male                      1.07 \[0.98--1.18\]          0.97 \[0.89--1.06\]
  Race                                                   
  White                     Reference                    Reference
  African Americans         **1.16 \[1.02--1.33\]**      1.03 \[0.90--1.18\]
  Others                    1.02 \[0.87--1.20\]          1.10 \[0.96--1.27\]
  Unknown                   0.35 \[0.05--2.57\]          0.99 \[0.29--3.37\]
  Location                                               
  Left                      Reference                    Reference
  NOS                       0.97 \[0.71--1.31\]          1.15 \[0.90--1.48\]
  Rectum                    0.87 \[0.75--1.01\]          0.95 \[0.83--1.08\]
  Right                     1.05 \[0.94--1.17\]          **1.22 \[1.10--1.35\]**
  Tumor size                                             
  \<=2 cm                   Reference                    Reference
  2--4 cm                   0.95 \[0.79--1.15\]          1.00 \[0.85--1.19\]
  4--6 cm                   1.00 \[0.83--1.20\]          1.10 \[0.94--1.29\]
  \>6 cm                    1.06 \[0.87--1.28\]          **1.25 \[1.05--1.48\]**
  N                         1.04 \[0.86--1.27\]          1.01 \[0.85--1.21\]
  Surgery                                                
  No                        Reference                    Reference
  Yes                       **0.77 \[0.65--0.91\]**      **0.86 \[0.75--0.995\]**
  Stage                                                  
  0/(Tis)                   Reference                    Reference
  I                         1.55 \[0.22--10.88\]         1.07 \[0.14--8.48\]
  II                        4.62 \[0.69--30.73\]         2.96 \[0.39--22.73\]
  III                       **6.96 \[1.06--45.70\]**     4.08 \[0.54--30.82\]
  IV                        **18.90 \[2.88--123.93\]**   **11.31 \[1.50--85.33\]**
  Unknown                   5.52 \[0.78--39.14\]         5.01 \[0.64--39.46\]
  Grade                                                  
  Low grade (I & II)        Reference                    Reference
  High grade (III & IV)     **1.35 \[1.20--1.52\]**      **1.38 \[1.25--1.53\]**
  NOS                       0.95 \[0.81--1.10\]          1.07 \[0.93--1.23\]
  Regional nodes positive                                
  \>=10                     Reference                    Reference
  0                         **0.48 \[0.39--0.59\]**      **0.37 \[0.31--0.46\]**
  1--3                      **0.61 \[0.52--0.73\]**      **0.50 \[0.43--0.57\]**
  4--9                      **0.80 \[0.68--0.95\]**      **0.70 \[0.61--0.80\]**
  Radiotherapy                                           
  No                                                     
  Yes                       1.07 \[0.92--1.26\]          1.00 \[0.87--1.15\]
  Unknown                   1.04 \[0.56--1.92\]          0.45 \[0.19--1.09\]
  Chemotherapy                                           
  No                        Reference                    Reference
  Yes                       **0.77 \[0.66--0.90\]**      0.99 \[0.86--1.13\]
  Marital status                                         
  Married                   Reference                    Reference
  Unmarried                 **1.19 \[1.08--1.32\]**      **1.11 \[1.01--1.21\]**
  Unknown                   0.88 \[0.70--1.11\]          1.12 \[0.91--1.37\]

**Note:**

KRAS MT, KRAS mutant; KRAS WT, KRAS wild type; HR, Hazard ratios; 95% CI, 95% confidence intervals; the widowed or single (never married or having a domestic partner) or divorced or separated patients was defined as unmarried; Tis, Tumor in situ; significant results were bolded.

Prognostic discrepancies were found in other variables between KRAS MT and WT CRC patients. The older age was a protective factor for KRAS MT patients (HR \< 1, *p* \< 0.05) but was not associated with the prognosis of KRAS WT patients (*p* \> 0.05). We found that the race of African American was a risk factor for KRAS MT patients but not for KRAS WT patients. The right side colon cancer was observed to have worse CSS than left side colon cancer in KRAS WT patients (HR \> 1, *p* \< 0.05) but not in KRAS MT patients (*p* \> 0.05). Moreover, we found that the chemotherapy was only a protective factor for KRAS MT patients (HR \< 1, *p* \< 0.05) but not for KRAS WT patients (*p* \> 0.05).

Nomogram construction and validation
------------------------------------

The LASSO, SCAD and MCP analyses all selected age, location, tumor size and stage, regional positive nodes amount, KRAS mutation status, chemotherapy experience and radiotherapy experience as the key prognostic variables of our nomogram ([Table 4](#table-4){ref-type="table"}). These variables were then used to construct the multivariate SH model based nomogram to predict the 1-year, 2-year and 3-year CRC specific death ([Fig. 3](#fig-3){ref-type="fig"}). Internal validation showed good calibration ([Figs. 4A](#fig-4){ref-type="fig"}--[4C](#fig-4){ref-type="fig"}, there were good agreements between the nomogram predicted CRC death and actual observed CRC death) and discrimination (AUC \> 0.75, [Fig. 4D](#fig-4){ref-type="fig"}) of current nomogram.
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###### Variable selection: estimated coefficients (SEs) for the current SH model.
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  Characteristics           LASSO    SCAD     MCP
  ------------------------- -------- -------- --------
  Age                       −0.022   −0.025   −0.028
  Sex                       0.000    0.000    0.000
  Race                      0.000    0.000    0.000
  Location                  −0.032   −0.041   −0.044
  Surgery                   −0.069   0.000    0.000
  Tumor size                0.017    0.027    0.025
  Tumor stage               0.226    0.233    0.233
  Grade                     0.000    0.000    0.000
  Regional nodes positive   0.097    0.105    0.105
  KRAS status               0.13     0.182    0.183
  Chemotherapy              0.314    0.384    0.383
  Radiotherapy              −0.061   −0.095   −0.095
  Marital status            0.000    0.000    0.000

**Note:**

LASSO, least absolute shrinkage and selection operator; SCAD, smoothly clipped absolute deviation (SCAD); MCP, measure--correlate-predict (MCP).

![Nomogram for predicting 1-year, 2-year and 3-year CSS of CRC patients who had KRAS testing.\
The nomogram is used by summing the points identified on the top scale for each independent variable and drawing a vertical line from the total points scale to the 1-year, 2-year and 3-year CSS to obtain the probability of survival. The total points projected to the bottom scale indicate the % probability of the 3-year survival. Age: 2, 20--29 years, 3, 30--39 years, 4, 40--49 years, 5, 50--59 years, 6, 60--69 years and 7, 70--79 years; Race: 1, Caucasian, 2, African American, 3, Other race and N, Unknown race; Tumor size: 2, "0--2 cm", 4, "2--4 cm", 6, "4--6 cm", \>6 = "\>6 cm", N, Unknown size; Tumor stage, 0, 0 stage (Tumor in situ), 1, I stage, 2, II stage, 3, III stage, 4, IV stage and N, Unknown stage; No. Nodes, the number of positive regional lymph nodes; KRAS status: 0, Wild type and 1, Mutation; Chemotherapy, 0, none/unknown and 1, yes; Radiotherapy, 0, none/unknown or refused, 1, beam radiation or combination of beam with implants or isotopes or radiation with method or source not specified or radioactive implants or radioisotopes and N, Recommended, unknown if administered.](peerj-08-9149-g003){#fig-3}

![Calibration curves for cox-based and SH based nomograms.\
(A--C) The calibration plots for predicting 1-year, 2-year and 3-year CSS of CRC patients; (D) the AUC plots for SH-based nomogram.](peerj-08-9149-g004){#fig-4}

Discussion
==========

The KRAS testing for metastatic CRC patients was recommended by the National Comprehensive Cancer Network (NCCN). The rate of KRAS testing for metastatic or non-metastatic CRC patients was increased in recent years according to SEER database ([Fig. S2](#supp-2){ref-type="supplementary-material"}). However, the association between KRAS mutation status and the prognosis of CRC patients remains unclear. A SEER based study ([@ref-7]) found that there was no association between KRAS mutation status and the OS of CRC. This might be a result of the limited follow up time, as they included the 2010--2012 data meanwhile had a last follow-up time of December 2013. Compared with this study, we included with 2010--2012 data while the last follow-up time was December 2015. The median survival time of our cohort was 33 months and the overall death rate of current study was 62.1%, indicating that our follow up time was relative sufficient. Furthermore, CRC patients were often diagnosed at an old age, therefore, competing risk analysis was more appropriate in the SEER based study. Our competing risk model found KRAS MT would shorten the CSS in CRC patients. Further subgroup analysis found that KRAS MT patients had worse CSS than KRAS WT patients among stage III or stage IV CRC patients or patients with left side colon cancer or rectal cancer. Moreover, the current study firstly built a competing nomogram for CRC patients who had KRAS testing.

Age was observed as a risk factor for the OS of CRC patients ([@ref-7]; [@ref-36]). However, CRC patients are usually elders who might have high potential risk of deaths from other diseases. Our competing risk model found the older age was not associated with worse CSS of CRC patients. Moreover, older KRAS MT patients might have better CSS than young patients.

Left colon cancer was found to be more sensitive to anti-EGFR targeted therapy than right colon cancer ([@ref-37]). The right side colon cancer was found to have more BRAF mutation than left side colon cancer, which might cause the resistant to anti-EGFR therapy ([@ref-35]) and worsen the prognosis ([@ref-27]). Hence, for left-sided colon cancer, KRAS WT CRC patients are more likely to be benefit from anti-EGFR targeted therapy and have better outcomes than KRAS MT patients. Indeed, we found KRAS mutation was an independent risk factor for left side colon cancer but not right side colon cancer. Moreover, in KRAS WT patients, we found right colon cancer had worse CSS than left side colon cancer meanwhile in KRAS MT patients, there was no significant prognostic difference between right and left side colon cancers.

We built an SH model-based nomogram to predict the probability of cancer specific death after a variable selection. Our nomogram was well validated. The predictors of current nomogram were easy to be obtained in clinical use. The increasing concern about competing risk had promoted researchers to develop competing risk nomograms for a groups of cancers ([@ref-5]; [@ref-16]; [@ref-18]; [@ref-29]; [@ref-38]).

There were certain limitations in our study. First, prognostic differences were found between KRAS codon 12 and codon 13 mutations ([@ref-13]). However, the detailed KRAS mutation pattern was not registered in SEER. The detailed anti-EGFR therapy and chemotherapy strategy were also missed. Second, other genetic variables, such as BRAF mutation and microsatellite instability (MSI), were also frequently occurred in CRC and associated with the prognosis of CRC ([@ref-15]; [@ref-28]). These data were also not available in SEER. Third, selection bias might exist in current study as we only included patients with complete information of included variables.

Conclusion
==========

This is the first population based competing risk study on the association between KRAS mutation status and the CRC prognosis. We found that KRAS mutation would worsen the CSS for patients with stage III and stage IV CRC, and for patients with cancers in the locations of left side colon and rectum. We constructed an SH based nomogram with good discrimination and calibration which might help the clinicians to predict the 1-year, 2-year and 3-year cancer specific death of CRC patients who had KRAS testing.
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###### The median survival time of different groups from SEER database after screening.

The current study included with 2010--2012 group (arrow), which exhibited similar median survival time as 2010 group.

###### 

Click here for additional data file.
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###### KRAS testing rates by years of metastatic CRC and non-metastatic CRC according to SEER.

###### 

Click here for additional data file.
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###### Raw data from SEER database.

The meanings of the code are available at the SEER website (<https://seer.cancer.gov>: \"SEER RESEARCH DATA RECORD DESCRIPTION\").

###### 

Click here for additional data file.

Additional Information and Declarations
=======================================

The authors declare that they have no competing interests.

[Dongjun Dai](#author-1){ref-type="contrib"} conceived and designed the experiments, performed the experiments, analyzed the data, prepared figures and/or tables, authored or reviewed drafts of the paper, and approved the final draft.

[Yanmei Wang](#author-2){ref-type="contrib"} performed the experiments, analyzed the data, prepared figures and/or tables, and approved the final draft.

[Liyuan Zhu](#author-3){ref-type="contrib"} performed the experiments, analyzed the data, prepared figures and/or tables, and approved the final draft.

[Hongchuan Jin](#author-4){ref-type="contrib"} conceived and designed the experiments, authored or reviewed drafts of the paper, and approved the final draft.

[Xian Wang](#author-5){ref-type="contrib"} conceived and designed the experiments, authored or reviewed drafts of the paper, and approved the final draft.

The following information was supplied regarding data availability:

The raw data from the SEER database is available in the [Supplemental File](#supplemental-information){ref-type="supplementary-material"}.
